-
PREFERENCES AND WILLINGNESS-TO-PAY FOR LYME DISEASE VACCINES IN THE UNITED STATES: A LATENT CLASS APPROACH
Aug 11, 2026, 17:16 PM -
USING CROSS-VALIDATION TO ASSESS MODEL SUITABILITY FOR NEW DECISION PROBLEMS: A CASE STUDY IN PREDIABETES
Aug 11, 2026, 17:16 PM -
PAEDIATRIC LAIV VACCINATION IN AUSTRIA: A COST-MINIMISATION ANALYSIS OF SCALING COVERAGE AND REDUCING HEALTHCARE BURDEN
Aug 11, 2026, 17:16 PM -
PHENOTYPING TENOSYNOVIAL GIANT CELL TUMOR (TGCT) AT POPULATION SCALE: VALIDATED LARGE LANGUAGE MODEL (LLM) EXTRACTION FROM US REAL-WORLD CLINICAL NOTES
Aug 11, 2026, 17:16 PM -
INTANGIBLE BURDENS AND THEIR RELENTLESS IMPACTS: BEYOND THE FINANCIAL COSTS OF LYSOSOMAL STORAGE DISORDERS (FABRY DISEASE, GAUCHER DISEASE TYPE 3, AND GM2 GANGLIOSIDOSES)
Aug 11, 2026, 17:16 PM -
A BAYESIAN LONGITUDINAL MULTILEVEL NETWORK META-REGRESSION MODEL FOR REPEATED CONTINUOUS OUTCOMES
Aug 11, 2026, 17:16 PM -
AI IN HEALTH ECONOMICS AND OUTCOMES RESEARCH SUFFERS FROM LOW EXPLAINABILITY, TRACEABILITY, REPRODUCIBILITY AND FROM HALLUCINATIONS: A TARGETED REVIEW OF CHALLENGES AND TECHNICAL MITIGATIONS
Aug 11, 2026, 17:16 PM -
THE "INVISIBLE" BURDEN: WORKPLACE DIFFICULTIES IN EARLY-STAGE RELAPSING-REMITTING MULTIPLE SCLEROSIS WITH LOW PHYSICAL DISABILITY
Aug 11, 2026, 17:16 PM -
ORIGINATOR PRICE REDUCTIONS AND UPTAKE-RELATED SAVINGS ASSOCIATED WITH BIOSIMILAR AVAILABILITY: A BUDGET IMPACT ANALYSIS OF 12 BIOLOGIC MOLECULES IN SOUTH KOREA
Aug 11, 2026, 17:16 PM -
INCLUSION OF ML-NMR RESULTS IN PROBABILISTIC SENSITIVITY ANALYSIS: BALANCING BIAS AND COMPUTATIONAL COST
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS OF APIXABAN VERSUS ACENOCOUMAROL FOR STROKE PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN ALGERIA
Aug 11, 2026, 17:16 PM -
SEASONAL BURDEN, REGIONAL VARIATION, AND HEALTH-SYSTEM SIGNALS IN IN-HOSPITAL PNEUMONIA MORTALITY
Aug 11, 2026, 17:16 PM -
LONG-TERM EFFICACY OF NETAKIMAB IN RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (R-AXSPA): SIMULATED TREATMENT COMPARISONS RESULTS
Aug 11, 2026, 17:16 PM -
IS GENERIC SUBSTITUTION A POLICY BLUEPRINT FOR BIOSIMILAR SUBSTITUTION IN COMMUNITY PHARMACY?
Aug 11, 2026, 17:16 PM -
DOES PRIMARY ENDPOINT TYPE INFLUENCE REGULATORY AND HTA OUTCOMES FOR EMA APPROVED ONCOLOGY MEDICINES IN ITALY?
Aug 11, 2026, 17:16 PM -
REACTOGENICITY OF NUVAXOVID AND OTHER COMMERCIALIZED COVID-19 VACCINES: A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS
Aug 11, 2026, 17:16 PM -
ESTIMATING THE PREVALENCE OF TURNER SYNDROME IN THE UNITED STATES AND EUROPE: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS
Aug 11, 2026, 17:16 PM -
AI-DRIVEN SYNTHETIC PATIENT GENERATION FRAMEWORK TO MODEL OBESITY USING THE CONSTANCES COHORT
Aug 11, 2026, 17:16 PM -
CYTOMEGALOVIRUS INFECTION IN PEDIATRIC KIDNEY TRANSPLANT RECIPIENTS RECEIVING CYTOMEGALOVIRUS PROPHYLAXIS: A SYSTEMATIC LITERATURE REVIEW
Aug 11, 2026, 17:16 PM -
EQUITY BY DESIGN: A NATIONWIDE GEOSPATIAL ASSESSMENT OF BRAZIL'S CAPACITY TO DELIVER INTRAVENOUS ALS THERAPIES
Aug 11, 2026, 17:16 PM
